Literature DB >> 20064187

Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?

U Wollina1, E Köstler, A Koch, H Riedel, U Stölzel.   

Abstract

BACKGROUND: Porphyria cutanea tarda (PCT) is regularly associated with changes in liver tissue. On the other hand, systematic investigations are lacking on whether there is a correlation between the severity of liver damage and chloroquine treatment. PATIENTS AND METHODS: During a 20-year period, liver biopsies were obtained in 89 patients with PCT confirmed by biochemical analysis of urine and feces and low-dose chloroquine therapy. Seventeen patients with alcohol-induced liver disease were excluded. In 8 of 63 patients, only a single biopsy was available. Classification of liver damage was performed according to the Riedel score. Electron microscopy was available from 24 patients. In a second group of patients, the HFE status was investigated and Berlin blue stains of liver biopsies were performed.
RESULTS: There was no correlation between the duration of cutaneous symptoms and liver pathology. After 12 months chloroquine treatment, 45 patients (81%) disclosed an improvement of liver pathology, nine (16%) had no change, and a worsening was observed in one patient (3%). All patients achieved a complete clinical and biochemical remission. In 13 of 16 patients with a relapse, there was again a deterioration of liver damage. Patients with HFE mutations had a significant higher risk (P < 0.05) for hepatic siderosis.
CONCLUSIONS: The severity of liver damage was not correlated with the disease duration. Chloroquine treatment resulted in PCT remission (clinical and biochemical) and in 81% to an improvement of liver morphology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20064187     DOI: 10.1111/j.1365-4632.2009.04205.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  4 in total

Review 1.  [Porphyrias-what is verified?]

Authors:  U Stölzel; I Kubisch; T Stauch
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 2.  [Porphyrias].

Authors:  U Stölzel; T Stauch; M O Doss
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

3.  Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis.

Authors:  H Salameh; H Sarairah; M Rizwan; Y-F Kuo; K E Anderson; A K Singal
Journal:  Br J Dermatol       Date:  2018-07-26       Impact factor: 9.302

4.  Use of antimalarials in dermatology.

Authors:  Falk R Ochsendorf
Journal:  J Dtsch Dermatol Ges       Date:  2010-07-29       Impact factor: 5.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.